A case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?

Authors

  • Theeb Osama Sulaiman HMC
  • Ahmed K A Yasin
  • Abdellatif Ismail

DOI:

https://doi.org/10.32677/yjm.v1i2.3684

Keywords:

Antineutrophil cytoplasmic antibody, Cyclophosphamide, Posterior reversible encephalopathy syndrome, Renal-pulmonary disease

Abstract

We reported a case of cyclophosphamide (CYP)-induced posterior reversible encephalopathy syndrome (PRES) in a 26-year-old previously healthy male patient who presented to the emergency department with a history of fever, shortness of breath, and hemoptysis. After extensive investigations, including bronchoscopy and autoimmune screening, he was diagnosed with the renal-pulmonary syndrome. The diagnosis of CYP-related PRES was based on the development of a neurological clinical picture supported by magnetic resonance imaging findings. The dose of CYP was decreased to 75 mg/day, and the patient’s symptoms improved after 3 days.

Downloads

Download data is not yet available.

Downloads

Published

2022-11-14

How to Cite

Osama Sulaiman, T., Yasin, A., & Ismail, A. (2022). A case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?. Yemen Journal of Medicine, 1(2), 103–107. https://doi.org/10.32677/yjm.v1i2.3684

Issue

Section

Case Report